The Role of B-Cell Depletion with Rituximab in the Treatment of Membranous Nephropathy: A Review of Emerging Evidence

Abstract

Introduction: Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults and is driven by an autoimmune process targeting the glomerulus. Standard therapies with corticosteroids and cytotoxic agents are associated with significant toxicity, creating a need for safer, more targeted treatments. Rituximab, a monoclonal antibody that depletes CD20-expressing B-cells, emerged as a rational therapeutic alternative.

Literature Review: A review of the pivotal early literature demonstrates the efficacy of rituximab for inducing remission in MN. The therapeutic strategy is based on the strong rationale of targeting the B-lymphocytes that serve as precursors to pathogenic autoantibody-producing plasma cells. Initial case reports and small pilot studies provided the first proof-of-concept, showing that rituximab could dramatically reduce proteinuria in patients with treatment-resistant disease. These findings were substantiated by larger, prospective, single-arm cohort studies. These studies confirmed that a course of rituximab led to partial or complete remission of proteinuria in a substantial proportion of patients, with a favorable safety profile compared to conventional immunosuppression. The clinical response was often observed to lag several months behind the successful depletion of circulating B-cells.

Conclusion: This body of emerging evidence established targeted B-cell depletion with rituximab as a highly promising and effective treatment strategy for membranous nephropathy. While awaiting validation from large-scale randomized trials, this research provided a strong foundation that altered the treatment landscape and heralded a shift toward targeted biological therapies for autoimmune kidney diseases.